Melatonin
Melatonin is a hormone naturally produced by the pineal gland that regulates sleep-wake cycles, widely available as an over-the-counter supplement.
Overview
Melatonin is a hormone produced primarily by the pineal gland in the brain, functioning as the body's principal biochemical signal for darkness and a central regulator of circadian rhythm — the internal clock that governs sleep-wake timing and numerous other physiological processes. Unlike most hormones, melatonin is widely available as an over-the-counter supplement in many countries, a regulatory status that has made it one of the most commonly used non-prescription sleep-related products worldwide. Its commercial accessibility, combined with widespread public interest in sleep quality, has generated an enormous consumer market and a cultural familiarity with melatonin that often exceeds the nuance of the underlying science.
The conversation around supplemental melatonin frequently conflates the hormone's well-established endogenous role in circadian signaling with the effects of exogenous supplementation — two related but distinct phenomena. The body's own melatonin production follows a finely tuned rhythm governed by light exposure, and the relationship between this endogenous process and the introduction of supplemental melatonin is more complex than the popular narrative of "taking a sleep hormone" might suggest. The amounts found in many commercial products far exceed what the pineal gland naturally produces, and the implications of this disparity for both efficacy and safety are active areas of scientific discussion. This page is educational and does not provide guidance on supplement use.
What it is
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine derived from the amino acid tryptophan, synthesized primarily in the pineal gland through a series of enzymatic steps that are suppressed by light exposure and activated by darkness. This light-dependent production cycle is why melatonin is often called the "darkness hormone" — its secretion typically rises in the evening as light diminishes, peaks during the nighttime hours, and falls toward morning. Beyond the pineal gland, melatonin is also produced in smaller quantities in other tissues, including the retina, gut, and bone marrow, where it may serve local signaling functions distinct from its circadian role.
As a supplement, melatonin is available in tablets, capsules, gummies, liquids, and dissolving formulations. Products vary widely in their actual melatonin content — independent laboratory analyses have documented substantial discrepancies between labeled and measured amounts across commercial products. Melatonin supplements may also contain serotonin as an unintended contaminant, a finding reported in analytical studies of the supplement market. The compound's regulatory classification varies by country: in the United States, it is sold as a dietary supplement without a prescription; in parts of Europe, Australia, and other regions, it is regulated more strictly, sometimes requiring a prescription. This regulatory variability reflects genuine uncertainty about how melatonin should be categorized — as a nutrient, a hormone, or something between the two.
Traditional use (educational)
Melatonin as a supplement has no traditional or historical use in the conventional sense. The hormone itself was identified and isolated in 1958 by Aaron Lerner and colleagues at Yale University, who named it for its ability to lighten skin pigmentation in frogs (from the Greek melas, meaning dark, and tonos, meaning labor or contraction). For several decades after its discovery, melatonin remained a subject of basic research in endocrinology and chronobiology rather than a consumer product.
The commercialization of melatonin as a supplement began in earnest in the 1990s in the United States, following a period of media attention and popular books that promoted it as a sleep aid and broadly beneficial hormone. This initial wave of consumer enthusiasm was not rooted in traditional healing systems or indigenous knowledge but rather in a translation — sometimes overenthusiastic — of emerging laboratory and clinical research into popular health narratives. The supplement's rapid adoption was facilitated by the 1994 Dietary Supplement Health and Education Act (DSHEA) in the United States, which allowed melatonin to be sold without the regulatory oversight applied to pharmaceutical drugs. Unlike herbs and botanicals with deep ethnobotanical histories, melatonin's cultural trajectory is entirely a product of modern biochemical research and regulatory frameworks.
What research says
The research literature on melatonin is substantial, spanning basic chronobiology, clinical trials of sleep-related applications, and exploratory studies across a range of other domains. The strongest evidence base concerns melatonin's relationship to circadian rhythm disruptions. Clinical trials examining melatonin supplementation in the context of jet lag have produced relatively consistent findings suggesting that appropriately timed supplementation may help realign sleep-wake timing after transmeridian travel. This specific application — circadian phase shifting — aligns closely with melatonin's known biological role as a timing signal and represents the area of greatest convergence between the endogenous hormone's function and the expected effect of exogenous supplementation.
For general sleep-onset difficulty in adults without a specific circadian disruption, the evidence is more equivocal. Meta-analyses of clinical trials have reported statistically significant but modestly sized associations between melatonin supplementation and reductions in sleep-onset latency (the time it takes to fall asleep). The clinical meaningfulness of these modest reductions — often measured in minutes — has been debated. The effects appear more consistent in older adults, a finding that some researchers attribute to age-related declines in endogenous melatonin production, though this explanation remains hypothetical. For overall sleep duration and sleep quality as subjectively reported, the evidence is less consistent, with significant variability across trials in population characteristics, outcome measures, and assessment tools.
Research in populations other than adults — particularly children with neurodevelopmental conditions — has generated a separate body of literature with its own evidence profile. Some studies have reported associations between melatonin supplementation and changes in sleep parameters in these populations, but the generalizability of these findings, the appropriate contexts for their application, and the long-term implications remain subjects of active discussion in the pediatric and neurodevelopmental research communities.
Beyond sleep, melatonin has been studied in exploratory contexts including oxidative stress, immune function markers, and pre-surgical contexts. These investigations are generally at an early stage, with small sample sizes and heterogeneous designs that limit the conclusions that can be drawn. Authoritative reference bodies, including NCCIH, characterize melatonin as having reasonable evidence for short-term use related to circadian timing but insufficient evidence for most other promoted applications.
Safety & interactions
Melatonin is generally described in safety literature as well-tolerated for short-term use in adults. The most commonly reported side effects include headache, next-day drowsiness, dizziness, and nausea. Because melatonin is a hormone with effects on circadian rhythm and potentially on other hormonal systems, the safety considerations extend beyond the typical profile associated with inert dietary supplements.
Interactions with several medication categories have been flagged in reference materials. Sedative medications and central nervous system depressants may produce additive drowsiness effects when combined with melatonin. Anticoagulant medications — particularly warfarin — have been noted as a potential interaction concern, based on limited case reports. Some immunosuppressant medications may theoretically interact with melatonin, given preliminary observations about melatonin's effects on immune function markers in laboratory settings. Medications related to blood sugar management are also commonly flagged, as some published research has explored melatonin's relationship to glucose metabolism and insulin sensitivity. The caffeine pathway is relevant as well — caffeine and melatonin share metabolic pathways in the liver, and concurrent caffeine consumption may alter melatonin's clearance rate. The long-term safety of chronic melatonin supplementation has not been established through rigorous, extended clinical trials, and this represents a significant gap in the evidence base given how widely and persistently the supplement is used.
Who should be cautious
Children and adolescents represent a population for whom caution is frequently emphasized in reference materials, given the limited long-term safety data and theoretical concerns about exogenous hormone supplementation during developmental periods. Despite widespread parental use of melatonin for children, authoritative sources generally advise clinical guidance for pediatric populations. Pregnant and breastfeeding individuals lack sufficient safety data from controlled studies, and most reference materials note the need for caution during these periods.
Individuals with autoimmune conditions are sometimes flagged due to preliminary observations about melatonin's relationship to immune function markers, though the clinical relevance of these observations is not well established. People with seizure-related conditions, depression, or other mood-related conditions are also mentioned in some reference databases as populations warranting awareness, given melatonin's involvement in neurotransmitter pathways. Individuals taking blood-thinning medications, blood pressure-lowering medications, immunosuppressive drugs, or medications related to blood sugar management should consider discussing melatonin supplementation with a qualified clinician. Older adults with hepatic or renal impairment may clear melatonin differently, and the implications of altered clearance for this population are not comprehensively studied.
Quality & sourcing considerations
The melatonin supplement market presents notable quality-control challenges. Independent analytical studies have documented that the actual melatonin content in commercial products frequently deviates from what the label declares — in some cases by substantial margins in both directions. A widely cited 2017 Canadian study of commercial melatonin supplements found that most products tested did not contain the labeled amount, with actual content ranging from a fraction to several times the declared quantity. Additionally, some products contained detectable serotonin, an unrelated neurotransmitter whose unintended presence in a supplement raises its own safety considerations.
These findings underscore the importance of sourcing melatonin products from manufacturers that participate in third-party testing programs, such as those offered by USP, NSF International, or ConsumerLab. The supplement's unregulated status in the United States means that product quality is largely dependent on manufacturer integrity and voluntary quality-assurance practices. Formulation type — immediate-release versus extended-release — also varies across products and may affect the compound's pharmacokinetic profile, though the clinical significance of these differences is not well characterized for most consumers. Given the documented variability in the market, individuals choosing to use melatonin supplements face meaningful uncertainty about what they are actually consuming unless they select products with verified third-party testing.
FAQs
Is melatonin a sleeping pill? No. Melatonin is a hormone involved in circadian timing — it signals to the body that darkness has arrived and helps regulate the sleep-wake cycle. It does not act through the same pharmacological mechanisms as prescription sedative medications, and its effects on sleep are generally understood to be related to circadian phase adjustment rather than direct sedation. The popular perception of melatonin as a "natural sleeping pill" oversimplifies its biological role.
Does the body build tolerance to supplemental melatonin? This question is frequently raised but not conclusively answered in the current evidence base. Some researchers have suggested that tolerance does not appear to develop in the way it does with sedative medications, while others note that long-term data are insufficient to draw firm conclusions. The question is complicated by the fact that melatonin is a hormone with feedback relationships to the body's own production, and the implications of long-term exogenous supplementation for endogenous production are not fully understood.
Why are melatonin supplements so popular for children? Parental interest in melatonin for children has grown substantially, driven in part by widespread availability and a perception of naturalness and safety. Some clinical research has examined melatonin supplementation in children with specific neurodevelopmental conditions affecting sleep, and these findings have permeated into broader consumer awareness. However, authoritative reference sources emphasize that routine supplementation in children should involve clinical guidance, particularly given the limited long-term safety data during developmental stages.
Does light exposure at night affect melatonin? Yes. The body's melatonin production is tightly linked to light-dark cycles. Exposure to bright light — particularly blue-spectrum light from screens and artificial lighting — during evening hours can suppress the pineal gland's melatonin output, delaying the natural rise in melatonin that typically accompanies nightfall. This relationship between light exposure and melatonin production is well established in chronobiology research and represents one of the most consistently documented aspects of melatonin physiology.
How does melatonin differ from prescription sleep medications? Prescription sleep medications typically act on neurotransmitter receptor systems (such as GABA receptors) to promote sedation or reduce wakefulness through direct pharmacological mechanisms. Melatonin, by contrast, functions primarily as a circadian timing signal rather than a sedative in the traditional pharmacological sense. The subjective experience of taking melatonin may feel different from taking a prescription sedative, and the two categories should not be considered interchangeable or equivalent in their mechanisms or risk profiles.